Cargando…
Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
The therapeutic armamentarium has significantly expanded since the approval of various CD19-targeting chimeric antigen receptor T cell (CAR-T) therapies in non-Hodgkin lymphoma (NHL). These CAR-Ts are patient-specific and require a complex, resource, and time-consuming process. While this appears pr...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8873350/ https://www.ncbi.nlm.nih.gov/pubmed/35212892 http://dx.doi.org/10.1007/s11864-021-00920-6 |